业绩稳定增长，盈利能力持续提升 杭叉集团2024年实现营业收入164.9亿元，同比增长1.15%（调整后）；归母净利润20.2亿元，同比增长 17.9%（调整后）。毛利率为23.6%，同比上升2.8个百分点；净利率为13.1%，同比上升1.8个百分点。 公司2025年一季度实现营业收入45.1亿元，同比增长8.0%；归母净利润4.4亿元，同比增长15.2%。毛利率 为20.5%，同比下降0.1个百分点；净利率为10.0%，同比上升0.4个百分点。 点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客 户，用作新媒体形势下研究信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿 订阅、接收或使用本订阅号中的任何信息。本订阅号难以设置访问权限，若给您造成不便， 敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相关人员为光大 证券的客户。 报告摘要 本订阅号是光大证券股份有限公司研究所（以下简称"光大证券研究所"）依法设立、独立运营的 官方唯一订阅号。其他任何以光大证券研究所名义注册的、或含有"光大证券研究"、与光大证券 研究 ...

贯彻高质量发展，利润、现金流各项财务指标表现优异营收端：实现稳健增长，海外占比提升至64%。 2024 年公司营收777.73 亿元，同比+6.22%；其中Q4 营业收入198.83 亿元，同比+12.49%，2024 年下半 年海外市场增速复苏，四季度营收增速优于全年。 1）全年分市场来看，海外营收占主营收入比重提升至64%。国内273.18 亿元，同比-3.35%，其中挖掘 机械实现正增长，非挖仍有下滑；海外485.13 亿元，同比+12.15%，维持较好增长，海外营收在主营业 务收入占比已达64%，同比+3.5pct，海外细分地区来看，亚澳205.7 亿元，同比+15.47%；欧洲123.2 亿 元，同比+1.86%；美洲102.8 亿元，同比+6.64%；非洲区域53.5 亿元，同比+44.02%，新兴市场总体表 现更好。 事件 2024 年营业收入777.73 亿元，同比增加6.22%；归母净利润59. 75亿元，同比增加31.98%。单季度表现 来看，Q4 营业收入198. 83亿元，同比增加12.49%；归母净利润11.07 亿元， 同比增加141.15%。 简评 预计公司2025-2027年实 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [11]. Core Views - The company, as a leading manufacturer in China's construction machinery industry, is expected to undergo a value reassessment in the new cycle, driven by internationalization, product expansion, and improved operational quality [3][6]. - The current upward trend in both domestic and overseas construction machinery markets supports the company's potential for value reassessment during the new upward cycle [9]. Summary by Sections Introduction - The report discusses the value reassessment of the company in the context of a new cycle, emphasizing the importance of demand-side analysis and the company's operational quality, product line expansion, and business layout [6][18]. Industry Trends - The domestic market is at the beginning of a new upward cycle, with significant growth in excavator sales, which increased by 38.3% year-on-year in Q1 2025 [7][21]. - The global market for construction machinery presents vast opportunities, with emerging markets showing sustained demand growth [48][49]. Company Analysis - The company is enhancing its international presence, with overseas revenue contributing 44% and gross profit contributing 47% in H1 2024 [8][9]. - Product line expansion includes strengthening its excavator business and increasing its presence in the mining machinery sector, which is expected to drive revenue and profit growth [8][9]. - Operational quality is improving, with anticipated increases in profitability and asset quality due to scale effects and a shift towards high-margin overseas revenue [9][9]. Investment Recommendations - The company is projected to achieve a net profit of 6.124 billion and 8.224 billion yuan in 2024 and 2025, respectively, with corresponding price-to-earnings ratios of 17 times and 12 times [9].

近日，广西柳工机械股份有限公司正式披露2024年年度报告，数据显示，公司在过去一年成绩斐然。 2024年柳工实现营业收入约300.63亿元，同比增长9.24%， 这一增速创历史新高 ；归属于上市公司股东的净利润约13.27亿元，同比大幅增长52.92%。 图：柳工2024年度财务指标 在国内房地产市场持续调整、工程机械行业整体处于周期底部修复阶段的大背景下，柳工凭借 加速出海与国内业务变革驱动 ， 实现营收与净利双增长 ，国际化与 电动化成为其高质量发展的核心动力。 当前， 工程机械行业面临诸多挑战 。受有效需求不足影响，本轮下行周期触底后，行业总销量仍处于低位。房地产及基建需求端改善不明显，更新换代需求有 限，同时出口量及出口金额增速进一步放缓，行业在周期底部艰难修复。2024年下半年以来，新增专项债发行放量、万亿国债落地，部分地区项目开工情况好转， 再加上大规模设备更新政策推出以及低基数效应，市场开始逐步恢复。 在这样的行业环境中， 柳工国内业务变革成效显著。 自混改以来，柳工国内营销大力开展质量、效率、动力变革，敏锐捕捉市场周期调整机遇。各产品线全面跑 赢行业，装载机继续保持龙头优势，挖掘机实现快速增长 ...

Core Viewpoint - The article emphasizes the characteristics that high-quality Chinese assets should possess, highlighting Guizhou Moutai's strong performance as a benchmark for investor confidence in a volatile global market [1][8]. Financial Performance - In 2024, Guizhou Moutai achieved total revenue of 170.9 billion yuan, a year-on-year increase of 15.71%, and a net profit attributable to shareholders of 86.228 billion yuan, up 15.38% year-on-year [1][2]. - The company plans to distribute a cash dividend of 276.24 yuan per 10 shares, totaling 34.671 billion yuan, which represents 75% of the net profit attributable to shareholders [2][3]. Product Performance - Moutai liquor generated revenue of 145.928 billion yuan in 2024, reflecting a 15.28% increase, while other series of liquor achieved 24.684 billion yuan, growing by 19.65% [3]. - The core product, Moutai liquor, continues to show stable revenue growth, while other series are emerging as new growth engines for the company [2][3]. Channel Optimization - Guizhou Moutai has developed a diversified sales channel system, with direct sales revenue reaching 74.843 billion yuan, an increase of 11.32% [4]. - The "i Moutai" digital marketing platform generated 20.024 billion yuan in revenue, enhancing consumer interaction and brand loyalty [4]. Brand Value and Internationalization - In 2024, Guizhou Moutai's brand value reached 87.298 billion USD, ranking first among liquor brands in the Kantar "BrandZ Most Valuable Chinese Brands" list [5]. - The company has accelerated its internationalization efforts, achieving over 5 billion yuan in export revenue for the first time, with high-value Moutai liquor exports increasing by over 40% [6][7]. Cultural Promotion - Guizhou Moutai has engaged in extensive cultural promotion activities, hosting 225 tasting events and attracting over 15,000 participants [6]. - The company has established a systematic approach to cultural branding, enhancing its international recognition and influence [7]. Overall Impact - Guizhou Moutai's strong financial performance, high dividend payouts, and effective brand and channel strategies collectively reinforce its position as a high-quality asset in the market, contributing to the overall development of the liquor industry [8].

Core Viewpoint - Heng Rui Medicine has made significant personnel changes following the impressive performance in its 2024 annual report, emphasizing its commitment to technological innovation and internationalization as core strategies [1][6]. Financial Performance - In 2024, Heng Rui Medicine reported a record revenue of 27.985 billion yuan, a year-on-year increase of 22.63%, and a net profit attributable to shareholders of 6.337 billion yuan, up 47.28% [2]. - The sales revenue from innovative drugs reached 13.892 billion yuan, accounting for over half of the company's total sales revenue, with a year-on-year growth of 30.6% despite increasing competition and pricing pressures [2]. - The company invested 8.228 billion yuan in research and development, with 6.583 billion yuan classified as expense-based R&D, representing 29.4% of total sales revenue [2]. Research and Development - Heng Rui Medicine has 14 complementary R&D centers across China, Japan, the United States, Australia, and Switzerland, with a global R&D team of over 5,500 people [2]. - The company has 90+ innovative products in clinical development and approximately 400 clinical trials ongoing domestically and internationally, ranking 8th in the global TOP25 pipeline scale pharmaceutical companies list by Citeline [4]. Strategic Partnerships and Licensing - Heng Rui Medicine has granted exclusive rights for the development, production, and commercialization of its GLP-1 class innovative drug and DLL3 ADC innovative drug to U.S. companies Kailera Therapeutics and IDEAYA Biosciences, respectively [3]. - The company entered into an agreement with Merck to license an oral small molecule project, receiving an upfront payment of 200 million USD and potential milestone payments up to 1.77 billion USD, along with possible sales royalties [4]. Talent Acquisition and Management - The company has intensified talent acquisition efforts, bringing in over 700 core talents in 2024, including more than 200 with doctoral degrees [6]. - Heng Rui Medicine is actively promoting internal talent development through various programs aimed at nurturing high-potential talents and enhancing management capabilities [6]. Market Focus - While Heng Rui Medicine has traditionally focused on oncology, it is expanding its research pipeline in metabolic, autoimmune, and other chronic disease areas, with 47 innovative pipelines in non-oncology fields now surpassing those in oncology [6].

内容概要：作为战略性支柱产业，中国船舶工业发展在政策指引下不断提速。进入21世纪后，船舶工业 的战略地位进一步提升，并且在强力的产业政策支持下进行自主化和产业转型升级。近年来，随着我国 航运业的稳步发展，国内各大造船企业发展持续向好，造船完工量、承接新船订单、手持船舶订单等总 体上也保持增长态势。2024年，我国船舶工业保持稳定向好的发展态势，造船三大指标全面增长。全国 造船完工量4818万载重吨，同比增长13.8%；新接订单量11305万载重吨，同比增长58.8%；手持订单量 20872万载重吨，同比增长49.7%。 相关上市企业：中国船舶（600150）、中远海控（601919）、天海防务（300008）、中船防务 （00317）、江龙船艇（300589）、中国重工（601989）、中国动力（600482）、亚光科技 （300123）、中远海特（600428）、锦江航运（601083）等。 相关企业：中国船舶集团有限公司、常熟市国瑞科技股份有限公司、智慧航海（青岛）科技有限公司、 中远海运重工有限公司、江南造船（集团）有限责任公司、江苏扬子江船业集团有限公司、武汉船用机 械有限责任公司、大连船舶重工集团有 ...

Core Viewpoint - Heng Rui Medicine (600276.SH) achieved record high revenue and net profit driven by innovative drugs, with a significant stock price increase recently [1][2][3] Financial Performance - In 2024, Heng Rui Medicine reported revenue of 27.985 billion yuan, a year-on-year increase of 22.63%, and a net profit of 6.337 billion yuan, up 47.28% year-on-year [1] - The company's innovative drug sales revenue reached 13.892 billion yuan, contributing over half of total sales revenue, with a year-on-year growth of 30.60% [3][4] Research and Development - Heng Rui Medicine's R&D investment reached a historical high of 8.228 billion yuan in 2024, representing a year-on-year increase of 33.79%, accounting for 29.40% of revenue [1][4] - Cumulatively, the company has invested over 44 billion yuan in R&D to date [1] Innovation and Product Development - The company expects over 40 innovative products to be approved for market in the next three years, covering various therapeutic areas including oncology and cardiovascular diseases [7][9] - In 2024, 10 innovative products were approved, including four first-class innovative drugs [7][8] Internationalization and Business Development - Heng Rui Medicine has initiated over 20 overseas clinical trials in countries such as the US, Europe, and Japan, with several products entering Phase III trials [11][12] - The company has engaged in 13 licensing transactions with global partners, with a potential total transaction value of approximately 14 billion USD [12][13]

Core Insights - The company reported a revenue of 29.009 billion yuan and a net profit of 4.328 billion yuan for 2024, marking the first decline in both revenue and net profit in nearly a decade due to new market challenges in the pharmaceutical sector [1] - Despite the challenges, the company's gross margin remained stable, and its R&D expenses exceeded 5 billion yuan for the first time, indicating a strong commitment to innovation [1][4] - The company aims to become an internationally influential innovative pharmaceutical enterprise, driven by a dual strategy of innovation and internationalization [1][6] Financial Performance - The company experienced a revenue decline of 28.3% in its oncology segment due to price reductions from centralized procurement, particularly affecting two key anti-tumor drugs [2] - The revenue from the mature drug segment reached 23.736 billion yuan, accounting for over 80% of total revenue, with stable growth from core products and new additions contributing significantly [2][3] Innovation and R&D - R&D expenses increased to 5.191 billion yuan, representing a 7.5% year-on-year growth and accounting for 21.9% of the mature drug segment's revenue [4] - The company has over 200 innovative drugs and formulations in development, with 160 clinical trials ongoing, including nearly 60 in Phase III [4][5] - The company received multiple approvals for new products and indications in 2024, enhancing its product portfolio and market resilience [3][4] Strategic Partnerships and Collaborations - The company has secured significant licensing agreements, including a $100 million upfront payment from AstraZeneca for a drug, with potential milestone payments totaling up to $15.5 billion [7] - The partnerships reflect the company's rapid innovation pace and the successful application of AI in drug development [6][7]

转自：北京日报客户端 日前，A股五大上市险企——中国人保、中国人寿、中国平安、中国太保、新华保险，2024年业绩已经 披露完毕。总体来看，2024年，五家险企合计实现归母净利润3475.71亿元，同比增长77.7%。其中，中 国人寿、中国太保、新华保险净利润均创历史新高。 具体来看，中国人保、中国人寿、中国平安、中国太保、新华保险2024年归母净利润分别为428.69亿 元、1069.35亿元、1266.07亿元、449.60亿元、262.29亿元，较上年同期分别增长88.24%、108.92%、 47.79%、64.95%、201.07%。多家险企分析认为，净利润同比大增背后，是资本市场回暖推动投资收益 提升所致。2024年，五家上市险企总投资收益率都超过了5%。 中国人寿副总裁 刘晖：2024年的投资业绩的确比2023年同比提升了3个百分点，创下近年来的新高，在 权益市场低迷的时候也能够坚定地入市，仅在2024年全年净加仓超过1000亿元，权益投资收益取得了很 好的增长。 新华保险董事长 杨玉成：拟向全体股东派发2024年末期现金股利每股1.99元，全年合计拟派发现金股利 78.9亿元，比去年派息金额增加 ...